SecBot SecBot
Biotech Drug Report Generated Jul 3, 2026

Amtagvi

IOVA·IOVANCE BIOTHERAPEUTICS, INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved (accelerated approval)
Time to market
Already approved and marketed (FDA accelerated approval Feb 16, 2024). Confirmatory Phase 3 (TILVANCE-301) is ongoing to convert to full approval.
Why 4/10
Amtagvi is already FDA-approved (Feb 2024) and generating growing commercial revenue (~$264M in FY2025). There is no pending PDUFA decision. The next major binary catalyst is the TILVANCE-301 Phase 3 confirmatory readout in frontline melanoma, but no hard date is available, the trial (N=670) is still enrolling with readout likely in 2027+. Without a dated binary in the ~12-month window, impactScore is capped at 4.
Actionable Insight NEUTRAL

Watch for TILVANCE-301 Phase 3 interim or topline results (undated but the key catalyst for converting accelerated to full approval and expanding into frontline) and quarterly revenue growth trajectory, Q2 2026 guidance is $86M-$88M. Also monitor IOV-LUN-202 NSCLC registrational data (Fast Track, potential launch 2H27). At ~$3.97 with a mean analyst target of $8.80 (177% upside), the stock prices in meaningful commercial execution but not a TILVANCE-301 success.

Price Chart

Loading chart...

Executive Summary

Amtagvi (lifileucel) is Iovance Biotherapeutics' first-in-class, FDA-approved tumor-infiltrating lymphocyte (TIL) cell therapy for advanced melanoma, the first T-cell therapy ever approved for a solid tumor. It received accelerated approval in February 2024 for patients who have already tried a PD-1 inhibitor. The drug generated ~$264M in total product revenue in FY2025 (61% YoY growth) with strong sequential acceleration (Q4 at $87M). Iovance guides FY2026 total revenue of $350M-$370M. The key upcoming catalyst is the TILVANCE-301 Phase 3 confirmatory trial, which is still enrolling and would expand lifileucel into the frontline melanoma setting. Competition includes Bristol Myers Squibb's approved IO triplet and other emerging TIL and cell therapies. The stock trades at ~$3.97 with a mean analyst target of $8.80 (177% implied upside) and a consensus rating of Buy (10 Buy, 3 Hold, 3 Strong Buy).

How It Works

A personalized one-time cell therapy. Doctors surgically remove some of the patient's tumor, extract immune cells called TILs (tumor-infiltrating lymphocytes) that naturally attack the cancer, multiply them into billions in a lab, and infuse them back into the patient. This gives the immune system a massive army of cancer-fighting cells. Before the infusion, the patient receives chemotherapy to clear out existing immune cells, making room for the new ones, plus high-dose IL-2 (Proleukin) afterward to keep them active.

Trial Status

Amtagvi received FDA accelerated approval on February 16, 2024 for advanced melanoma after PD-1 therapy. The confirmatory Phase 3 trial TILVANCE-301 (NCT05727904, N=670) is actively enrolling across 75+ global sites, evaluating lifileucel + pembrolizumab vs pembrolizumab alone in the frontline setting. Iovance also has a registrational trial in NSCLC (IOV-LUN-202, Fast Track Designation, potential launch 2H27) and a Phase 2 registrational trial in soft tissue sarcomas (IOV-SAR-201) starting in Q2 2026.

The Two-Sided Case

▲ Bull Case6
First and only FDA-approved TIL therapy for solid tumors, first-mover advantage in a new treatment class (source: FiercePharma)
Strong commercial momentum: FY2025 product revenue of ~$264M (+61% YoY), Q4 at $87M (+30% QoQ); FY2026 guidance $350M-$370M
90+ authorized treatment centers established in the US, with Australian TGA approval received June 2026 for third global market entry (source: SEC 8-K filing July 2, 2026)
Mean analyst price target $8.80 vs current ~$3.97, 177% implied upside; 13 of 16 analysts at Buy or Strong Buy
Deep pipeline: TILVANCE-301 Phase 3 frontline melanoma, IOV-LUN-202 NSCLC (Fast Track), IOV-SAR-201 sarcoma registrational trial, IOV-5001 next-gen TIL (source: SEC 8-K filing)
Cash position ~$319M (3/31/26) with runway into 2028, reducing near-term dilution risk (source: SEC 8-K filing July 2, 2026)
▼ Bear Case6
Accelerated approval requires confirmatory data; if TILVANCE-301 Phase 3 fails to meet endpoints, the drug could face withdrawal or label restriction, a binary risk with no hard readout date yet (source: FDA press release)
Complex manufacturing logistics: personalized cell therapy requires tumor harvest, centralized manufacturing, and infusion, limiting scalability vs off-the-shelf alternatives (source: FiercePharma)
Competition intensifying: Bristol Myers Squibb's IO triplet in melanoma and other emerging TIL/cell therapies could erode market share (source: FiercePharma, AInvest)
High pricing (~$515,000 list per course) creates reimbursement hurdles; net revenue realization may lag adoption (source: Business Model Canvas analysis)
Company remains unprofitable with negative EPS (-$0.19 in Q1 2026); dilution risk as authorized shares increased from 500M to 650M (source: SEC 8-K filings, analyst estimates)
Short interest elevated: short ratio hit 57% on July 1, 2026 (z-score 2.72), indicating significant bearish positioning (source: FINRA short volume data)

Upcoming Catalysts

  • TILVANCE-301 Phase 3 confirmatory trial results (undated, but key catalyst for frontline approval and converting accelerated to full approval)
  • Q2 2026 earnings (guidance $86M-$88M revenue), commercial execution signal
  • IOV-LUN-202 NSCLC registrational data update (Fast Track, potential 2H27 launch)
  • IOV-SAR-201 Phase 2 soft tissue sarcoma trial initiation (2H 2026)
  • IOV-5001 (IL-12 tethered TIL) Phase 1/2 basket trial initiation (2H 2026)
  • Global regulatory expansion beyond US and Australia (EU/UK potential)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

IOVANCE BIOTHERAPEUTICS, INC. 8-K IOVA ·Originating report

Sources · 12

Hover a chip for the title
1 pharmtech.com2 fiercepharma.com3 drugs.com4 onclive.com5 tipranks.com6 sec.gov7 sec.gov8 fda.gov9 tilvance-301.com10 fiercepharma.com11 ainvest.com12 ainvest.com